Sale by Michael Wortley of 894 shares of Reata Pharmaceuticals

RETADelisted Stock  USD 109.67  3.31  2.93%   
About 62% of Reata Pharmaceuticals' investor base is looking to short. The analysis of current outlook of investing in Reata Pharmaceuticals suggests that many traders are alarmed regarding Reata Pharmaceuticals' prospects. The current market sentiment, together with Reata Pharmaceuticals' historical and current headlines, can help investors time the market. In addition, many technical investors use Reata Pharmaceuticals stock news signals to limit their universe of possible portfolio assets.
  
Filed transaction by Reata Pharmaceuticals Inc officer. General open market or private sale of non-derivative or derivative security

Read at macroaxis.com
Reata insider trading alert for sale of class a common stock by Michael Wortley, Chief Legal Officer, on 17th of May 2023. This event was filed by Reata Pharmaceuticals Inc with SEC on 2023-05-17. Statement of changes in beneficial ownership - SEC Form 4. Michael Wortley currently serves as vice president chief legal officer of Reata Pharmaceuticals

Reata Pharmaceuticals Fundamental Analysis

We analyze Reata Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Reata Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Reata Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Working Capital

Working Capital Comparative Analysis

Reata Pharmaceuticals is currently under evaluation in working capital category among its peers. Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .

Reata Pharmaceuticals Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Reata Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Reata Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Reata Pharmaceuticals by comparing valuation metrics with similar companies.

Peers

Reata Pharmaceuticals Related Equities

CVACCureVac NV   4.74   
0%
100.0%
VIRVir Biotechnology   1.27   
0%
26.0%
KRYSKrystal Biotech   0.26   
0%
5.0%
AKROAkero Therapeutics   0.22   
4.0%
0%
MDGLMadrigal Pharmaceuticals   0.98   
20.0%
0%
TERNTerns Pharmaceuticals   1.58   
33.0%
0%
PTCTPTC Therapeutics   2.73   
57.0%
0%
VKTXViking Therapeutics   2.88   
60.0%
0%
SRPTSarepta Therapeutics   3.33   
70.0%
0%
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.

Other Consideration for investing in Reata Stock

If you are still planning to invest in Reata Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Reata Pharmaceuticals' history and understand the potential risks before investing.
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Bonds Directory
Find actively traded corporate debentures issued by US companies
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges